Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Future Innovation in Oncology: Update Bulletin # 2 [January 2019]

Product Code:
Publication Date:
January 2019

This edition presents key opinion leader (KOL) views on data presentations given at American Society of Hematology’s Annual Meeting 2018 (ASH 2018), held in December 2018. Topics covered include: Regeneron’s new data for REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, including promising clinical results in follicular lymphoma and diffuse large B-cell lymphoma; Celgene’s results from the TRANSCEND-CLL-004 trial assessing JCAR017 in patients with relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma; Kite’s updated results from the ZUMA-3 trial of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia.

Business Questions:

• What are the experts reactions to the results of REGN1979’s Phase I dose-finding trial in relapsed or refractory non-Hodgkin’s lymphoma?
• According to KOLs, what are the likely next steps for the development of REGN1979?
• What are KOLS opinions on the Phase I data from the TRANSCEND-CLL-004 study?
• What is the potential of JCAR017 as a future treatment for chronic lymphocytic leukaemia, as a monotherapy and/or in combination with ibrutinib (Imbruvica; AbbVie/Janssen)?
• Where will JCAR017 fit in the treatment paradigm for chronic lymphocytic leukaemia?
• What are KOLs opinions of the results of KTE-X19 in the ZUMA-3 trial in adults with relapsed or refractory acute lymphoblastic leukaemia?
• How does KTE-X19’s safety profile compare to other therapies?


All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved